PEPGEN INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
PEPGEN INC. (PEPG) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $3.31 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- PEPGEN INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $3.31M, a 40.20% increase year-over-year.
- PEPGEN INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $2.85M, a 16.81% decline year-over-year.
- PEPGEN INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $2.38M, a 26.32% decline year-over-year.
- PEPGEN INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $2.36M, a 17.44% decline year-over-year.
- PEPGEN INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $10.61M, a 7.40% decline from fiscal 2024.
- PEPGEN INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $11.46M, a 62.56% increase from fiscal 2023.
- PEPGEN INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $7.05M, a 47.97% increase from fiscal 2022.
- PEPGEN INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $4.76M, a 210.50% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.31M 10-Q · filed 2026-08-06 | $6.17M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $2.85M 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $10.61M 10-K · filed 2026-03-04 | |||
| 2025-09-30 | $2.38M 10-Q · filed 2025-11-12 | $4.74M derived: sum of 2 quarters · filed 2026-08-06 | $8.17M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | $2.36M 10-Q · filed 2026-08-06 | $5.79M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $3.43M 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $11.46M 10-K · filed 2026-03-04 | |||
| 2024-09-30 | $3.23M 10-Q · filed 2025-11-12 | $6.09M derived: sum of 2 quarters · filed 2025-11-12 | $8.11M derived: sum of 3 quarters · filed 2025-11-12 | |
| 2024-06-30 | $2.86M 10-Q · filed 2025-11-12 | $4.88M derived: sum of 2 quarters · filed 2025-11-12 | ||
| 2024-03-31 | $2.02M 10-Q · filed 2025-11-12 | |||
| 2023-12-31 | $7.05M 10-K · filed 2025-02-24 | |||
| 2023-09-30 | $1.94M 10-Q · filed 2024-11-07 | $3.78M derived: sum of 2 quarters · filed 2024-11-07 | $5.13M derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | $1.84M 10-Q · filed 2024-11-07 | $3.19M derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $1.35M 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | $4.76M 10-K/A · filed 2024-03-29 | |||
| 2022-09-30 | $1.36M 10-Q · filed 2023-11-08 | $2.59M derived: sum of 2 quarters · filed 2023-11-08 | $3.40M derived: sum of 3 quarters · filed 2023-11-08 | |
| 2022-06-30 | $1.23M 10-Q · filed 2023-11-08 | $2.04M derived: sum of 2 quarters · filed 2023-11-08 | ||
| 2022-03-31 | $815.00K 10-Q · filed 2023-11-08 | |||
| 2021-12-31 | $1.53M 10-K · filed 2023-03-23 | |||
| 2021-09-30 | $348.00K 10-Q · filed 2022-11-10 | $677.00K derived: sum of 2 quarters · filed 2022-11-10 | $865.00K derived: sum of 3 quarters · filed 2022-11-10 | |
| 2021-06-30 | $329.00K 10-Q · filed 2022-11-10 | $517.00K derived: sum of 2 quarters · filed 2022-11-10 | ||
| 2021-03-31 | $188.00K 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |